211 related articles for article (PubMed ID: 24565013)
1. Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery.
Nathan PJ; Phan KL; Harmer CJ; Mehta MA; Bullmore ET
Curr Opin Pharmacol; 2014 Feb; 14():54-61. PubMed ID: 24565013
[TBL] [Abstract][Full Text] [Related]
2. Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption.
Nathan PJ; Bakker G
Psychopharmacology (Berl); 2021 May; 238(5):1255-1263. PubMed ID: 31900526
[TBL] [Abstract][Full Text] [Related]
3. The role of imaging in proof of concept for CNS drug discovery and development.
Wong DF; Tauscher J; Gründer G
Neuropsychopharmacology; 2009 Jan; 34(1):187-203. PubMed ID: 18843264
[TBL] [Abstract][Full Text] [Related]
4. Use of non-invasive neuroradiological methods in research of psychoactive drugs.
Henigsberg N; Kovacić Z; Kalember P
Psychiatr Danub; 2007 Sep; 19(3):234-7. PubMed ID: 17914326
[TBL] [Abstract][Full Text] [Related]
5. Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics.
Bifone A; Gozzi A
Expert Opin Drug Discov; 2012 Nov; 7(11):1071-82. PubMed ID: 22971143
[TBL] [Abstract][Full Text] [Related]
6. Role of functional magnetic resonance imaging in drug discovery.
Paulus MP; Stein MB
Neuropsychol Rev; 2007 Jun; 17(2):179-88. PubMed ID: 17436113
[TBL] [Abstract][Full Text] [Related]
7. Using NMR approaches to drive the search for new CNS therapeutics.
Borsook D; Becerra L
Curr Opin Investig Drugs; 2010 Jul; 11(7):771-8. PubMed ID: 20571972
[TBL] [Abstract][Full Text] [Related]
8. Use of functional imaging across clinical phases in CNS drug development.
Borsook D; Becerra L; Fava M
Transl Psychiatry; 2013 Jul; 3(7):e282. PubMed ID: 23860483
[TBL] [Abstract][Full Text] [Related]
9. Relating Translational Neuroimaging and Amperometric Endpoints: Utility for Neuropsychiatric Drug Discovery.
Li J; Schwarz AJ; Gilmour G
Curr Top Behav Neurosci; 2016; 28():397-421. PubMed ID: 27023366
[TBL] [Abstract][Full Text] [Related]
10. Resting-State Functional Connectivity-Based Biomarkers and Functional MRI-Based Neurofeedback for Psychiatric Disorders: A Challenge for Developing Theranostic Biomarkers.
Yamada T; Hashimoto RI; Yahata N; Ichikawa N; Yoshihara Y; Okamoto Y; Kato N; Takahashi H; Kawato M
Int J Neuropsychopharmacol; 2017 Oct; 20(10):769-781. PubMed ID: 28977523
[TBL] [Abstract][Full Text] [Related]
11. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
Sahu JK; Mishra AK
Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
[TBL] [Abstract][Full Text] [Related]
12. The role of fMRI in drug discovery.
Wise RG; Tracey I
J Magn Reson Imaging; 2006 Jun; 23(6):862-76. PubMed ID: 16649197
[TBL] [Abstract][Full Text] [Related]
13. What is the value of human FMRI in CNS drug development?
Wise RG; Preston C
Drug Discov Today; 2010 Nov; 15(21-22):973-80. PubMed ID: 20813202
[TBL] [Abstract][Full Text] [Related]
14. Neuroimaging-based biomarkers in psychiatry: clinical opportunities of a paradigm shift.
Fu CH; Costafreda SG
Can J Psychiatry; 2013 Sep; 58(9):499-508. PubMed ID: 24099497
[TBL] [Abstract][Full Text] [Related]
15. CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
Hutson PH; Clark JA; Cross AJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():171-187. PubMed ID: 27575715
[TBL] [Abstract][Full Text] [Related]
16. Drug discovery in psychiatric illness: mining for gold.
Elmer GI; Kafkafi N
Schizophr Bull; 2009 Mar; 35(2):287-92. PubMed ID: 19297381
[TBL] [Abstract][Full Text] [Related]
17. Opportunities and challenges in drug discovery targeting metabotropic glutamate receptor 4.
Volpi C; Fallarino F; Mondanelli G; Macchiarulo A; Grohmann U
Expert Opin Drug Discov; 2018 May; 13(5):411-423. PubMed ID: 29486616
[TBL] [Abstract][Full Text] [Related]
18. Applications of functional magnetic resonance imaging in psychiatry.
Mitterschiffthaler MT; Ettinger U; Mehta MA; Mataix-Cols D; Williams SC
J Magn Reson Imaging; 2006 Jun; 23(6):851-61. PubMed ID: 16652410
[TBL] [Abstract][Full Text] [Related]
19. Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation.
Hellyer S; Leach K; Gregory KJ
Curr Opin Pharmacol; 2017 Feb; 32():49-55. PubMed ID: 27842256
[TBL] [Abstract][Full Text] [Related]
20. A Window into the Brain: Advances in Psychiatric fMRI.
Zhan X; Yu R
Biomed Res Int; 2015; 2015():542467. PubMed ID: 26413531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
